06 Nov IU Angel Network Invests in PrecisionCare AI to Advance Breakthrough in Soft Tissue Therapy
INDIANAPOLIS, Ind. – The IU Angel Network, an investment vehicle of IU Ventures, today announced an investment in PrecisionCare AI, a Boomerang Ventures portfolio company pioneering Quantifiable Soft Tissue Manipulation (QSTM™)–a first-of-its-kind technology delivering objective, data-driven insights for physical therapists. Based on years of research, QSTM is designed to optimize treatment, personalize care, and improve patient outcomes as a new standard in musculoskeletal therapy.
Each year, millions of patients undergo physical therapy, and as many as 80% of those visits include soft tissue manual therapy. Yet today, those treatments remain largely subjective, with few measurable ways to capture treatment history, process, or outcomes. This lack of standardization can lead to inconsistent care and limited clinical evidence. PrecisionCare AI addresses this challenge by combining smart hardware and AI-powered analytics to give therapists real-time feedback and digital records, reducing variability and supporting evidence-based practice.
The technology originated at IU, where Terry Loghmani, PT, Ph.D., Associate Professor in the Department of Physical Therapy, identified the need for quantifiable metrics in soft tissue therapy. Dr. Loghmani co-developed the QSTM platform through Health Smart Technologies. Boomerang Ventures acquired the company in 2023, relaunching it as PrecisionCare AI with exclusive licensing rights to the IU-developed technology.
Jennifer Holmes, a MedTech leader with 30 years of executive experience, serves as CEO. Throughout her career, Jennifer has consistently accelerated revenue growth, led operations and commercialization, spearheaded succession planning, and managed complex change initiatives. Recently, as CEO of Rehab Boost, Inc., she successfully guided the company through an acquisition, selling its assets and intellectual property to MedBridge, a Brentwood Associates (private equity firm) portfolio company.
“The current approach to soft tissue manipulation lacks standardization and objective metrics, making it difficult for therapists to ensure consistent treatment and optimal patient outcomes,” Holmes said. “Our system closes that gap by providing real-time, objective feedback and digital records for soft tissue manipulation.”
The new investment will allow PrecisionCare AI to complete its validation pilot with ATI Physical Therapy, advance software and hardware development, expand clinical partnerships, and pursue additional non-dilutive funding.
“PrecisionCare AI represents a fundamental leap forward in evidence-based rehabilitation,” said Olivia Schmitt-Metz, senior analyst at IU Ventures. “With Jennifer’s leadership and deep commercialization expertise, the company is well-positioned to set a new industry standard for musculoskeletal care.”
National Science Foundation (NSF) I-Corp program findings reinforce market demand: 97% of surveyed clinicians said they want tools to measure soft tissue therapy. Early validation studies and clinical collaborations position QSTM as a “gamechanger” in delivering reproducible, high-quality care.
Holmes emphasized the strategic value of the IU Angel Network’s involvement:
“IU’s commitment to translational research and clinical validation aligns perfectly with our mission. Having the backing of the IU Angel Network sends a powerful signal to the Midwest investment community that PrecisionCare AI is ready to scale with evidence-based impact.”
About IU Ventures
IU Ventures invests in and supports IU-affiliated early-stage companies. Its investment programs include the IU Philanthropic Venture Fund, IU Angel Network, Shoebox Fund and Innovate Indiana Fund. It further supports IU founders through the Executive in Residence Program and IU Founders and Funders Network. Each program takes unique approaches to accelerate and support the positive impacts that entrepreneurs affiliated with IU already achieve across the world. http://www.iuventures.com/
About PrecisionCare AI
PrecisionCare AI is transforming musculoskeletal care through Quantifiable Soft Tissue Manipulation (QSTM™), an AI-powered solution providing real-time clinical insights and measurable outcomes. By combining advanced analytics with smart hardware, PrecisionCare AI empowers therapists to personalize care, improve patient outcomes, and set a new standard for evidence-based rehabilitation. https://www.precisioncare-ai.com/
Media Contacts
Jennifer Holmes
PrecisionCare AI
jennifer.holmes@boomerang.vc